VCEL vs. AMRX
VCEL (Vericel Corporation) and AMRX (Amneal Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — VCEL in Biotechnology, AMRX in Drug Manufacturers - Specialty & Generic. Over the past 10 years, VCEL returned 35.21%/yr vs -5.11%/yr for AMRX. Their 0.22 correlation means their historical movements had little consistent relationship.
Performance
VCEL vs. AMRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, VCEL achieves a 27.63% return, which is significantly lower than AMRX's 45.40% return. Over the past 10 years, VCEL has outperformed AMRX with an annualized return of 35.21%, while AMRX has yielded a comparatively lower -5.11% annualized return.
VCEL
- 1D
- -3.47%
- 1M
- -2.17%
- 6M
- 27.74%
- YTD
- 27.63%
- 1Y
- 28.99%
- 3Y*
- 9.38%
- 5Y*
- -2.79%
- 10Y*
- 35.21%
- ALL TIME*
- -10.26%
AMRX
- 1D
- -0.97%
- 1M
- 6.82%
- 6M
- 33.92%
- YTD
- 45.40%
- 1Y
- 133.97%
- 3Y*
- 79.45%
- 5Y*
- 30.02%
- 10Y*
- -5.11%
- ALL TIME*
- 11.78%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $32.37M | $32.67M | $30.54M | |
| $25.08M | $24.07M | $25.61M |
VCEL vs. AMRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
VCEL Vericel Corporation | 27.63% | -34.42% | 54.20% | 35.19% | -32.98% | 27.27% | 77.47% | 0.00% | 219.27% | 81.67% |
AMRX Amneal Pharmaceuticals, Inc. | 45.40% | 59.09% | 30.48% | 205.03% | -58.46% | 4.81% | -5.19% | -64.38% | -18.74% | 25.66% |
Correlation
The correlation between VCEL and AMRX is 0.37, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.37 |
Correlation (3Y) Balances recent behavior with more history. | 0.32 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.31 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.28 |
Correlation (All Time) Calculated using the full available price history since Jan 15, 2009 | 0.22 |
The correlation between VCEL and AMRX shifts across timeframes, from 0.22 (all time) to 0.37 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
VCEL:
$2.35B
AMRX:
$5.85B
VCEL:
$0.47
AMRX:
$0.48
VCEL:
97.57
AMRX:
37.97
VCEL:
0.68
AMRX:
1.32
VCEL:
7.72
AMRX:
1.92
VCEL:
6.33
AMRX:
182.01
VCEL:
$306.30M
AMRX:
$3.12B
VCEL:
$228.38M
AMRX:
$1.23B
VCEL:
$38.45M
AMRX:
$447.79M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
VCEL vs. AMRX — Risk / Return Rank
VCEL
AMRX
VCEL vs. AMRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Vericel Corporation (VCEL) and Amneal Pharmaceuticals, Inc. (AMRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VCEL | AMRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.39 | ||
| Sortino ratioReturn per unit of downside risk | -3.43 | ||
| Omega ratioGain probability vs. loss probability | 1.14 | 1.58 | -0.44 |
| Calmar ratioReturn relative to maximum drawdown | 1.02 | 6.07 | -5.05 |
| Martin ratioReturn relative to average drawdown | 2.27 | 15.13 | -12.86 |
Loading charts...
Drawdowns
VCEL vs. AMRX - Drawdown Comparison
The maximum VCEL drawdown since its inception was -99.88%, roughly equal to the maximum AMRX drawdown of -97.52%. Use the drawdown chart below to compare losses from any high point for VCEL and AMRX.
Loading charts...
Drawdown Indicators
| VCEL | AMRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.88% | -97.52% | -2.36% |
Max Drawdown (1Y)Largest decline over 1 year | -31.03% | -22.25% | -8.78% |
Max Drawdown (3Y)Largest decline over 3 years | -52.52% | -26.80% | -25.72% |
Max Drawdown (5Y)Largest decline over 5 years | -70.46% | -78.29% | +7.83% |
Max Drawdown (10Y)Largest decline over 10 years | -73.97% | -95.87% | +21.90% |
Current DrawdownCurrent decline from peak | -96.74% | -64.30% | -32.44% |
Average DrawdownAverage peak-to-trough decline | -89.89% | -54.42% | -35.47% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.96% | 8.91% | +5.05% |
Volatility
VCEL vs. AMRX - Volatility Comparison
Vericel Corporation (VCEL) and Amneal Pharmaceuticals, Inc. (AMRX) have volatilities of 10.15% and 9.86%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| VCEL | AMRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.15% | 9.86% | +0.29% |
Volatility (6M)Calculated over the trailing 6-month period | 30.27% | 25.71% | +4.56% |
Volatility (1Y)Calculated over the trailing 1-year period | 47.94% | 33.29% | +14.65% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 52.75% | 50.81% | +1.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 63.04% | 65.25% | -2.21% |
Dividends
VCEL vs. AMRX - Dividend Comparison
Neither VCEL nor AMRX has paid dividends to shareholders.
Financials
VCEL vs. AMRX - Financials Comparison
This section allows you to compare key financial metrics between Vericel Corporation and Amneal Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
VCEL vs. AMRX - Profitability Comparison
VCEL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Vericel Corporation reported a gross profit of 56.40M and revenue of 77.46M. Therefore, the gross margin over that period was 72.8%.
AMRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Amneal Pharmaceuticals, Inc. reported a gross profit of 334.51M and revenue of 796.20M. Therefore, the gross margin over that period was 42.0%.
VCEL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Vericel Corporation reported an operating income of 434.00K and revenue of 77.46M, resulting in an operating margin of 0.6%.
AMRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Amneal Pharmaceuticals, Inc. reported an operating income of -1.30M and revenue of 796.20M, resulting in an operating margin of -0.2%.
VCEL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Vericel Corporation reported a net income of 2.21M and revenue of 77.46M, resulting in a net margin of 2.9%.
AMRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Amneal Pharmaceuticals, Inc. reported a net income of 57.66M and revenue of 796.20M, resulting in a net margin of 7.2%.
Frequently Asked Questions
VCEL and AMRX have a correlation of 0.37, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
VCEL has higher volatility (10.15%) compared to AMRX (9.86%). In terms of maximum drawdown, VCEL dropped -99.88% vs AMRX's -97.52%.
AMRX currently has the higher Sharpe Ratio (4.08 vs 0.69), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for VCEL and AMRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer